Why the study?
The etiology of chest pain in hypertrophic cardiomyopathy is diverse, and myocardial bridging has been associated with hypertrophic cardiomyopathy, chest pain, and accelerated atherosclerosis.
Does the prevalence of myocardial bridging and coronary artery disease differ between patients with hypertrophic cardiomyopathy and matched controls?
Does the prevalence of myocardial bridging and coronary artery disease differ between patients with hypertrophic cardiomyopathy and matched controls?
Answers are grounded in this paper and cite their sources.
In patients with hypertrophic cardiomyopathy, myocardial bridging is twice as common as in matched controls but is not associated with chest pain or worse outcomes, while CAD prevalence is similar.
The etiology of chest pain in hypertrophic cardiomyopathy (HC) is diverse and includes coronary artery disease (CAD) as well as HC-specific causes. Myocardial bridging (MB) has been associated with HC, chest pain, and accelerated atherosclerosis. We compared HC patients with age-, gender- and CAD pre-test probability-matched outpatients presenting with chest pain to investigate differences in the presence of MB and CAD using coronary computed tomography angiography (CCTA). We studied 84 HC patients who underwent CCTA and compared these with 168 matched controls (age 54 ± 11 years, 70% men, pre-test probability 12% [5% to 32%]). MB, calcium score, plaque morphology and presence and extent of CAD were assessed for each patient. Linear mixed models were used to assess differences between cases and controls. MB was more often seen in HC patients (50% vs 25%, p <0.001). Calcium score and the presence of obstructive CAD were similar in both groups (9 [0 to 225] vs 4 [0 to 82] and 18% vs 19%; p = 0.22 and p = 0.82). In the HC group, MB was associated with pathogenic DNA variants (p = 0.04), but not with the presence of chest pain (74% vs 76%, p = 0.8), nor with worse outcome (log-rank p = 0.30). In conclusion, the prevalence and extent of CAD was equal among patients with and without HC, demonstrating that pre-test risk prediction using the CAD Consortium clinical risk score performs well in HC patients. MB was twice as prevalent in the HC group compared with matched controls, but was not associated with chest pain or decreased event-free survival in these patients.
No takes yet. Share an insight, caveat, or question.
Velde et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: